Search Results Search Sort by RelevanceMost Recent Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Medicine and Society Oct 2019 How Should Decision Aids Be Used During Counseling to Help Patients Who Are “Genetically at Risk”? Natalie Evans, PhD, Suzanne Metselaar, PhD, Carla van El, PhD, Nina Hallowell, DPhil, MA, and Guy Widdershoven, PhD Prognostic uncertainty about risk creates demand for ongoing communication and facilitated reflection about goals and values. AMA J Ethics. 2019;21(10):E865-872. doi: 10.1001/amajethics.2019.865. Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029. Viewpoint Jun 2008 Medical Care for the Elderly: Should Limits Be Set? Commentary 1 Daniel Callahan, PhD Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care? Virtual Mentor. 2008;10(6):404-407. doi: 10.1001/virtualmentor.2008.10.6.oped1-0806. Medicine and Society Aug 2019 Does Incorporating Cost-Effectiveness Analysis Into Prescribing Decisions Promote Drug Access Equity? Michael J. DiStefano, MBE and Jonathan S. Levin, MPH Advances in CEA methodology might integrate equity at the cost of transparency. AMA J Ethics. 2019;21(8):E679-685. doi: 10.1001/amajethics.2019.679. Case and Commentary Aug 2019 How Should Physicians Steward Limited Resources While Ensuring That Patients Can Access Needed Medicines? Pete Croughan and Rebekah E. Gee, MD, MPH Louisiana has a subscription model for hepatitis C treatment, but costly medications challenge states’ capacities to cover patients. AMA J Ethics. 2019;21(8):E630-635. doi: 10.1001/amajethics.2019.630. State of the Art and Science Aug 2019 Evolving Medicaid Coverage Policy and Rebates Jennifer A. Ohn, MPH and Anna Kaltenboeck, MA Ethics questions arise about the usefulness of a system that pegs Medicaid drug spending to net prices negotiated by others in the market. AMA J Ethics. 2019;21(8):E645-653. doi: 10.1001/amajethics.2019.645. Policy Forum Aug 2019 Why Are Biosimilars Not Living up to Their Promise in the US? Mike Z. Zhai, Ameet Sarpatwari, JD, PhD, and Aaron S. Kesselheim, MD, JD, MPH Overall utilization of the few biosimilars currently available to patients has been limited. AMA J Ethics. 2019;21(8):E668-678. doi: 10.1001/amajethics.2019.668. AMA Code Says Aug 2019 AMA Code of Medical Ethics’ Opinions Related to Prescription Drugs Rachel F. Harbut and Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics offers guidance on stewardship and professionalism. AMA J Ethics. 2019;21(8):E642-644. doi: 10.1001/amajethics.2019.642. State of the Art and Science Aug 2019 Are Medicaid Closed Formularies Unethical? Leah Rand, DPhil and Govind Persad, JD, PhD Closed formularies can be justified when they enable spending on other socially valuable aims, but they can single out poor patients. AMA J Ethics. 2019;21(8):E654-660. doi: 10.1001/amajethics.2019.654. Pagination First page « First Previous page ‹ Previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page Next › Last page Last »
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Medicine and Society Oct 2019 How Should Decision Aids Be Used During Counseling to Help Patients Who Are “Genetically at Risk”? Natalie Evans, PhD, Suzanne Metselaar, PhD, Carla van El, PhD, Nina Hallowell, DPhil, MA, and Guy Widdershoven, PhD Prognostic uncertainty about risk creates demand for ongoing communication and facilitated reflection about goals and values. AMA J Ethics. 2019;21(10):E865-872. doi: 10.1001/amajethics.2019.865.
Case and Commentary Dec 2019 Using the 4-S Framework to Guide Conversations With Patients About CRISPR Lisa S. Lehmann, MD, PhD, MSc Empathic communication skills help motivate understanding of safety, significance of harms, impact on succeeding generations, and social consequences. AMA J Ethics. 2019;21(12):E1029-1035. doi: 10.1001/amajethics.2019.1029.
Viewpoint Jun 2008 Medical Care for the Elderly: Should Limits Be Set? Commentary 1 Daniel Callahan, PhD Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care? Virtual Mentor. 2008;10(6):404-407. doi: 10.1001/virtualmentor.2008.10.6.oped1-0806.
Medicine and Society Aug 2019 Does Incorporating Cost-Effectiveness Analysis Into Prescribing Decisions Promote Drug Access Equity? Michael J. DiStefano, MBE and Jonathan S. Levin, MPH Advances in CEA methodology might integrate equity at the cost of transparency. AMA J Ethics. 2019;21(8):E679-685. doi: 10.1001/amajethics.2019.679.
Case and Commentary Aug 2019 How Should Physicians Steward Limited Resources While Ensuring That Patients Can Access Needed Medicines? Pete Croughan and Rebekah E. Gee, MD, MPH Louisiana has a subscription model for hepatitis C treatment, but costly medications challenge states’ capacities to cover patients. AMA J Ethics. 2019;21(8):E630-635. doi: 10.1001/amajethics.2019.630.
State of the Art and Science Aug 2019 Evolving Medicaid Coverage Policy and Rebates Jennifer A. Ohn, MPH and Anna Kaltenboeck, MA Ethics questions arise about the usefulness of a system that pegs Medicaid drug spending to net prices negotiated by others in the market. AMA J Ethics. 2019;21(8):E645-653. doi: 10.1001/amajethics.2019.645.
Policy Forum Aug 2019 Why Are Biosimilars Not Living up to Their Promise in the US? Mike Z. Zhai, Ameet Sarpatwari, JD, PhD, and Aaron S. Kesselheim, MD, JD, MPH Overall utilization of the few biosimilars currently available to patients has been limited. AMA J Ethics. 2019;21(8):E668-678. doi: 10.1001/amajethics.2019.668.
AMA Code Says Aug 2019 AMA Code of Medical Ethics’ Opinions Related to Prescription Drugs Rachel F. Harbut and Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics offers guidance on stewardship and professionalism. AMA J Ethics. 2019;21(8):E642-644. doi: 10.1001/amajethics.2019.642.
State of the Art and Science Aug 2019 Are Medicaid Closed Formularies Unethical? Leah Rand, DPhil and Govind Persad, JD, PhD Closed formularies can be justified when they enable spending on other socially valuable aims, but they can single out poor patients. AMA J Ethics. 2019;21(8):E654-660. doi: 10.1001/amajethics.2019.654.